Indication
In combination with 5-fluorouracil/leucovorin/oxaliplatin/docetaxel (FLOT) chemotherapy as neoadjuvant and adjuvant treatment, followed by adjuvant durvalumab monotherapy, for the treatment of adults with resectable gastric or gastro‑oesophageal junction adenocarcinoma.
Medicine details
- Medicine name:
- durvalumab (Imfinzi)
- SMC ID:
- SMC2944
- Pharmaceutical company
- AstraZeneca UK Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Publication due date:
- TBC
- SMC meeting date:
- TBC
- Patient group submission deadline:
- TBC